H

Hans Biomed Corp
KOSDAQ:042520

Watchlist Manager
Hans Biomed Corp
KOSDAQ:042520
Watchlist
Price: 30 750 KRW 11.41% Market Closed
Market Cap: ₩416B

Net Margin

-34.9%
Current
Declining
by 19.4%
vs 3-y average of -15.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-34.9%
=
Net Income
₩-31.3B
/
Revenue
₩89.8B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-34.9%
=
Net Income
₩-31.3B
/
Revenue
₩89.8B

Peer Comparison

Country Company Market Cap Net
Margin
KR
Hans Biomed Corp
KOSDAQ:042520
358.4B KRW
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
391.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
173.2B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.9B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 88% of companies in Korea
Percentile
12th
Based on 2 632 companies
12th percentile
-34.9%
Low
-168 471.3% — -2.9%
Typical Range
-2.9% — 5.8%
High
5.8% — 21 012.5%
Distribution Statistics
Korea
Min -168 471.3%
30th Percentile -2.9%
Median 1.9%
70th Percentile 5.8%
Max 21 012.5%

Hans Biomed Corp
Glance View

Market Cap
416B KRW
Industry
Biotechnology

Hans Biomed Corp. engages in the manufacture and sale of graft material and silicon products. The company is headquartered in Seoul, Seoul. The company went IPO on 2009-10-09. The firm mainly provides three categories of products: skin-implant materials, bone-implant materials and silicone products. Its skin-implant materials are used for burn treatment and skin graft under the brand names of SureDerm, BellaGen and GPS. Its bone-implant materials include allogeneic bones, xenogenous bones and synthetic bones used in dentistry, orthopedic and others, which are under the brand names of SureFuse, ExFuse and SureOss. Its silicone products are used for treatments of scars and for breast implant and others, which are under the brand names of BellaGel and Scar Clinic. In addition, it provides hair transplanters and others.

Intrinsic Value
20 517.24 KRW
Overvaluation 33%
Intrinsic Value
Price
H
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-34.9%
=
Net Income
₩-31.3B
/
Revenue
₩89.8B
What is Hans Biomed Corp's current Net Margin?

The current Net Margin for Hans Biomed Corp is -34.9%, which is below its 3-year median of -15.5%.

How has Net Margin changed over time?

Over the last 3 years, Hans Biomed Corp’s Net Margin has decreased from 8.3% to -34.9%. During this period, it reached a low of -34.9% on Oct 30, 2025 and a high of 8.3% on Aug 30, 2022.

Back to Top